Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484664 | 1.00 | LTA4H (0.49) | LTA4HELANEACEMEN1KMT2A | |
| SCHEMBL18619639 | 0.90 | ELANE (0.45) | ELANEACECMA1SIGMAR1CCR1 | |
| SCHEMBL18619612 | 0.89 | CCR1 (0.56) | LTA4HELANEACEMEN1KMT2A | |
| SCHEMBL20484735 | 0.89 | CCR1 (0.56) | LTA4HELANEACEMEN1KMT2A | |
| SCHEMBL18619615 | 0.83 | ACE (0.50) | ACEMEN1KMT2ACMA1ACE2 | |
| SCHEMBL20484748 | 0.83 | ACE (0.50) | ACEMEN1KMT2ACMA1ACE2 | |
| SCHEMBL18619614 | 0.81 | ACE (0.59) | LTA4HACEMEN1KMT2ACMA1 | |
| SCHEMBL20484547 | 0.81 | ACE (0.59) | LTA4HACEMEN1KMT2ACMA1 | |
| SCHEMBL15251740 | 0.80 | KMT2A (0.59) | LTA4HACEKMT2AACE2CCR1 | |
| SCHEMBL18621647 | 0.80 | CCR1 (0.53) | ELANEACECMA1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) (US) | 2018-09-06 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | MALT1, BCL3, BCL6 | LTA4H 1346/4885ELANE 2960/4885ACE 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.